A form of mitofusin 2 (Mfn2) lacking the transmembrane domains and the COOH-terminal end stimulates metabolism in muscle and liver cells. Am J Physiol Endocrinol Metab 305: E1208 -E1221, 2013. First published August 13, 2013; doi:10.1152/ajpendo.00546.2012.-Mitofusin 2 (Mfn2), a protein that participates in mitochondrial fusion, is required to maintain normal mitochondrial metabolism in skeletal muscle and liver. Given that muscle Mfn2 is repressed in obese or type 2 diabetic subjects, this protein may have a potential pathophysiological role in these conditions. To evaluate whether the metabolic effects of Mfn2 can be dissociated from its function in mitochondrial dynamics, we studied a form of human Mfn2, lacking the two transmembrane domains and the COOH-terminal coiled coil (⌬Mfn2). This form localized in mitochondria but did not alter mitochondrial morphology in cells or in skeletal muscle fibers. The expression of ⌬Mfn2 in mouse skeletal muscle stimulated glucose oxidation and enhanced respiratory control ratio, which occurred in the absence of changes in mitochondrial mass. ⌬Mfn2 did not stimulate mitochondrial respiration in Mfn2-deficient muscle cells. The expression of ⌬Mfn2 in mouse liver or in hepatoma cells stimulated gluconeogenesis. In addition, ⌬Mfn2 activated basal and maximal respiration both in muscle and liver cells. In all, we show that a form of Mfn2 lacking mitochondrial fusion activity stimulates mitochondrial function and enhances glucose metabolism in muscle and liver tissues. This study suggests that Mfn2 regulates metabolism independently of changes in mitochondrial morphology. mitochondrial dynamics; diabetes; mitochondrial respiration; mitochondrial fusion MITOCHONDRIAL MORPHOLOGY, response to apoptotic stimuli, mitochondrial metabolism, and mitochondrial quality control are all, in part, controlled through the balance between mitochondrial fusion and fission (33, 47) . Mitochondrial fusion in mammalian cells is controlled by mitofusin 1 and 2 (Mfn1, Mfn2) proteins and by OPA1. Mfn1 and Mfn2 explain outer mitochondrial membrane fusion, while OPA1 is responsible for inner mitochondrial membrane fusion. Mfn2 is an outer mitochondrial membrane protein of 757 residues in humans. The COOH-terminal part of the protein contains the transmembrane domains (residues 615-648 aa) and the coiled-coil 2 domain (HR2, residues 693-747 aa). The HR2 domain permits the tethering of Mfn2 with either Mfn2 or Mfn1 located in a neighboring mitochondrion (29). In addition to its participation in mitochondrial fusion, Mfn2 is also localized in endoplasmic reticulum (ER) mitochondrial contact sites and regulates the tethering of the ER to mitochondria and calcium homeostasis in mouse embryo fibroblasts (15). Thus, Mfn2 has pleiotropic cellular roles and regulates cell proliferation, oxidative metabolism, autophagy, and mitochondrial antiviral signaling protein (4, 13, 22, 37, 51). It has also been recently documented that ablation of Mfn1 and Mfn2 causes mitochondrial DNA depletion, an observation that indicates that these proteins are required for mitochondrial DNA stability (12).
mitochondrial dynamics; diabetes; mitochondrial respiration; mitochondrial fusion MITOCHONDRIAL MORPHOLOGY, response to apoptotic stimuli, mitochondrial metabolism, and mitochondrial quality control are all, in part, controlled through the balance between mitochondrial fusion and fission (33, 47) . Mitochondrial fusion in mammalian cells is controlled by mitofusin 1 and 2 (Mfn1, Mfn2) proteins and by OPA1. Mfn1 and Mfn2 explain outer mitochondrial membrane fusion, while OPA1 is responsible for inner mitochondrial membrane fusion. Mfn2 is an outer mitochondrial membrane protein of 757 residues in humans. The COOH-terminal part of the protein contains the transmembrane domains (residues 615-648 aa) and the coiled-coil 2 domain (HR2, residues 693-747 aa). The HR2 domain permits the tethering of Mfn2 with either Mfn2 or Mfn1 located in a neighboring mitochondrion (29) . In addition to its participation in mitochondrial fusion, Mfn2 is also localized in endoplasmic reticulum (ER) mitochondrial contact sites and regulates the tethering of the ER to mitochondria and calcium homeostasis in mouse embryo fibroblasts (15) . Thus, Mfn2 has pleiotropic cellular roles and regulates cell proliferation, oxidative metabolism, autophagy, and mitochondrial antiviral signaling protein (4, 13, 22, 37, 51) . It has also been recently documented that ablation of Mfn1 and Mfn2 causes mitochondrial DNA depletion, an observation that indicates that these proteins are required for mitochondrial DNA stability (12) .
Mfn2 is relevant in human disease. Thus, mutations in Mfn2 have been reported in patients affected by Charcot-MarieTooth neuropathy type 2A (14, 49, 54) . In addition, we have previously reported that Mfn2 mRNA is reduced in skeletal muscle of obese subjects and in type 2 diabetic patients (3, 26) . Moreover, massive weight loss induced by bariatric surgery causes a marked induction in Mfn2 expression in nondiabetic morbidly obese subjects (3, 24, 36) . In this regard, studies performed in non-muscle and muscle cell cultures indicate that the silencing of Mfn2 activity reduces the capacity to oxidize substrates (4, 37) . Our laboratory has demonstrated that Mfn2 deficiency in skeletal muscle causes mitochondrial dysfunction, which is characterized by reduced respiratory control ratio, reduced glucose oxidation, reduced expression of OXPHOS subunits, and reduced activity of respiratory Complex IV, which occurs in the absence of changes in ATP concentrations or in mitochondrial mass (44) . Furthermore, Mfn2 ablation causes defective insulin signaling in skeletal muscle and in liver (44) . In the present study, we analyzed whether the metabolic effects of Mfn2 are dependent on changes in mitochondrial morphology. This was done by expressing a short form of human Mfn2 that is inactive as a mitochondrial fusion protein in muscle and liver cells.
METHODS

Animal care.
All animal experiments were done in compliance with guidelines established by the University of Barcelona's Committee on Animal Care. Mice were kept under a 12:12-h dark-light period and provided with a standard chow diet and water ad libitum. Tissues used for DNA and RNA purification or protein extraction were prepared as described previously (32, 45) .
In vivo gene transfer. For electrotransfer studies, pCMVhMfn2⌬614-757 (⌬Mfn2) (37) or pDSRed2-Mito (Clontech) vectors were purified using a plasmid kit (Endofree; Qiagen, Crawley, UK) and dissolved in 0.9% NaCl. Ten-week-old mice (C57BL6/J, purchased from Harlan) were anesthetized with ketamine-xylazine and 1 h before electrotransfer muscles were pretreated with hyaluronidase (10 U/muscle) (18, 35) . Afterward, naked plasmids were injected into the tibialis anterior, gastrocnemius, and quadriceps of both hindlimbs. We established that the optimal amount of plasmid to achieve acceptable protein expression was 60 g and 100 g DNA in the former and latter, respectively. Ten pulses of 20 ms each were applied to each hindlimb at 175 V/cm and 1 Hz using an electroporator (ECM 830; BTX, Holliston, MA). The control animals were subjected to the same procedure after injection of an empty vector. Experiments were performed 2 wk after the electrotransfer for pCMV-hMfn2⌬614-757 (⌬Mfn2) vector or 8 days after electrotransfer for pDsRed2-Mito vector.
For the hepatic expression of ⌬Mfn2, male C57BL6J mice were fed standard laboratory food (weighed 20 Ϯ 3 g at the time of the studies). Animals were anesthetized with inhaled isoflurane. Pure recombinant virus [2 ϫ 10 9 plaque-forming units (pfu)], suspended in 0.2 ml of PBS, was injected into anesthetized mice through the tail vein. Animals were allowed to recover and were fed standard food ad libitum. Five days after adenovirus infusion, mice were subjected to a pyruvate challenge. To this end, mice were injected with 2 g/kg pyruvate (Sigma) intraperitoneally, with blood glucose measured at 0, 15, 30, 60, and 120 min time points. Blood glucose values were determined using a One Touch II glucose monitor (Lifescan). Thereafter, animals were euthanized. Blood samples were collected from the heart, centrifuged at 1,300 g for 15 min at 4°C in 1.5-ml centrifuge tubes containing EDTA, and stored at Ϫ20°C before measurement of insulin concentrations with a mouse insulin-specific radioimmunoassay kit (Crystalchem). Liver samples were collected, snap-frozen in liquid nitrogen, and stored at Ϫ80°C.
In vivo metabolic measurements and insulin signaling studies. Serum samples were taken between 10 AM and 12 noon after an overnight fast or at the same time in fed conditions. Blood glucose was assayed with an Accu-Chek glucose monitor (Roche Diagnostics). Plasma was immediately separated by centrifugation at 4°C and stored at Ϫ80°C until assay. A glucose tolerance test (GTT) was performed on mice fasted 16 h overnight. Glucose was measured at time 0, followed by intraperitoneal injection of 2 g/kg glucose. Blood glucose was also measured at 5, 15, 30, 60, 90, and 120 min after injection. Plasma insulin was measured using the Ultra Sensitive Mouse Insulin Elisa Kit (Crystal Chem) at 0, 15, 30, and 60 min after injection.
Cell culture and adenoviral transduction. C2C12 myoblasts were grown and allowed to differentiate into myotubes as previously described (8, 27) . At day 3 of differentiation, myotubes were transduced for 36 h at a multiplicity of infection (MOI) of 100 pfu/cell, and all the experiments were performed 48 h after infection. FaO cells were grown in Coon's modified Ham's-F12 medium supplemented with 10% FBS and 2 mM glutamine. Infection with adenoviruses was performed in Coon's modified Ham's-F12 medium supplemented with 0.2% (wt/vol) BSA (infection medium) for 2 h at an MOI of 50 pfu/cell. After infection, cells were incubated in infection medium for a further 16 h before the experiment was performed.
GFP, used as control, and hMfn2⌬614-757 (⌬Mfn2) were cloned by recombination into the pAdeno-CMV-V5 adenoviral vector (Invitrogen) using the Gateway system. Ad-miRCt (encoding for a control miRNA) and Ad-miR2 (encoding for 5 siRNA against Mfn2) have been previously reported (44) . Adenoviruses were generated by transfection of the adenoviral expression vectors in human embryonic kidney cell line (HEK 293). The adenoviruses generated were then amplified in HEK 293 cells, titrated using the Adeno-XTM Rapid Titer kit (Clontech), and used directly for cell transduction.
Lentivirus production and cell infection. Lentiviral vectors were packed using pMDLg/pRRE, pRSV-Rev, and pMD2.G plasmids. HEK 293T cells were transfected with pLKO.1-puro constructs for mouse mRNA Mfn2 (5=-GCTACAGCTCATCATCAGTTA-3= TRCN0000080610, Sigma-Aldrich) a third generation packing system for 24 h at 37°C and incubated for additional 24 h at 33°C to facilitate lentiviral production. After 48 h of lentiviral particle production, C2C12 cells were infected with filtered lentiviral medium (derived from HEK 293T cultures) supplemented with 2 g/ml polybrene. Cells were then selected by incubation with 2.5 mg/ml puromycin in the complete medium.
Subfractionation of purified mitochondria. Mitochondria from rat heart, skeletal muscle, and brown adipose tissue were obtained by differential centrifugation as described (37) , except that the tissues were homogenized using a motor-driven glass-Teflon mortar and pestle for 10 strokes at 1,000 rpm (heart, skeletal muscle) or at 500 rpm for 2-4 stokes (brown adipose tissue). To separate inner and outer mitochondrial membranes, we used digitonin. Fresh mitochondria were treated with digitonin (1.2%) as described (43) . Briefly, mitochondria suspended in isolation medium (70 mM sucrose, 220 mM mannitol, 2.0 mM HEPES, 0.5 mg/ml BSA, pH 7.4) were mixed with an equal volume of digitonin buffer (1.2%) at 0°C for 15 min. The mixture was centrifuged for 15 min at 1,900 g, and the first fraction containing mitoplasts and mitochondria with unbroken outer membranes was recovered. Finally, the outer membrane-rich fraction was recovered after centrifugation of the above supernatant at 35,000 g for 20 min. The different fractions were analyzed by Western blot analysis. To investigate the association of Mfn2 with mitochondrial membranes, mitochondria (50 g of protein, Bradford Bio-Rad protein assay) were treated with sodium carbonate or with different detergents.
Respiration studies in permeabilized muscle fibers or in cultured cells. Oxygen consumption was measured in permeabilized muscle fibers at 37°C by high-resolution respirometry with the Oxygraph-2k (Oroboros Instruments), as described (2, 6, 30) . Briefly, mice were anesthetized with ketamine-xylazine, and tibialis muscle was removed and placed on a plastic Petri dish containing 1 ml of ice-cold isolation solution [10 mM Ca-EGTA buffer (2.77 mM CaK 2EGTA ϩ 7.23 mM K2EGTA), 20 mM imidazole, 20 mM taurine, 50 mM K-MES, 3 mM K2HPO4, 6.5 mM MgCl2, 5.7 mM ATP, 15 mM phosphocreatine, and 0.5 mM DTT, pH 7.1]. Individual fiber bundles were separated with two pairs of sharp forceps and then permeabilized for 30 min in 2 ml of ice-cold isolation solution containing saponin 50 g/ml. After rinsing of muscle bundles in respiration medium (EGTA 0.5 mM, MgCl2·6H2O 3mM, taurine 20 mM, KH2PO4 10 mM, HEPES 20 mM, BSA 1 g/l, K-lactobionate 60 mM, sucrose 110 mM, pH 7.1), we weighed and transferred them (typically 2-4 mg wet wt) into an oxygraph chamber containing 2 ml of air-saturated respiration medium. Resting respiration (state 4, absence of adenylates) was determined by the addition of 10 mM glutamate and 2 mM malate as the Complex I substrate supply, and state 3 respiration was then assessed by the addition of 2.5 mM ADP. We examined ADP control of coupled respiration and uncoupling control through the addition of the protonophore carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone (FCCP; optimum concentration for maximal flux); 0.5 M rotenone and 2.5 M antimycin A were added to inhibit Complexes I and III, respectively, to observe nonmitochondrial respiration. All respiration measurements were made in triplicate.
Respirometry of cultured cells was performed using the XF24 extracellular flux analyzer (Seahorse Bioscience). Oxygen consumption was measured in routine conditions (DMEM ϩ 5.5 mM glucose) and after the sequential addition of 1 g/ml oligomycin (Complex V inhibitor), 0.3 M FCCP (uncoupler) and 0.1 M rotenone and antimycin A. All substrates, uncouplers, and inhibitors were purchased from Sigma.
Glucose oxidation in the incubated muscle. Mice were anesthetized with ketamine-xylazine, and tibialis muscle was carefully dissected and placed in 1 ml of cold Krebs-Ringer bicarbonate-HEPES buffer (pH 7.4) supplemented with 5 mmol/l glucose until all the muscles had been collected. Muscles were preincubated for 30 min at 37°C in 2 ml of Krebs-Ringer bicarbonate-HEPES buffer containing 2% BSA (fatty acid-free BSA; Sigma, St Louis, MO) and 5 mmol/l glucose (incubation medium). The medium was gassed continuously with 95% O2-5% CO2. The medium was then removed and replaced by 2 ml of fresh incubation medium containing 1 Ci/ml D-[U- 14 C]glucose (Amersham Biosciences). Muscles were incubated for 60 min at 37°C. Gassing was terminated after an initial 15 min. Test tubes were hermetically sealed with turnover flange rubber stoppers (SaintGobain Verneret, Charny, France) with a center well that contained a piece of filter paper saturated with 200 l of 1 M KOH. At the end of the incubation, medium was acidified with 0.3 ml of 0.5N H 2SO4, and gaseous 14 CO2 released after the acidification was trapped in the filter paper. The vials were incubated at 37°C for 60 min, and the filter papers were removed and transferred to vials for liquid scintillation counting.
Glucose production assay. FaO hepatoma cells were cultured in six-well plates (1.4 ϫ 10 6 cells/well) in DMEM with 10% FBS. The medium was then replaced with 1 ml of glucose production buffer consisting of glucose-free DMEM (pH 7.4), without phenol red, supplemented with 20 mM sodium lactate and 2 mM sodium pyruvate. After a 3-h incubation, 0.5 ml of medium was collected and the glucose concentration measured with a colorimetric glucose assay kit (Sigma). The readings were then normalized to the total protein content determined from the whole cell lysates.
Enzymatic activities. The enzymatic activities of respiratory chain complexes and citrate synthase were measured spectrophotometrically in total lysates of tibialis muscles. Using described spectrophotometric methods (5, 17, 40) , we determined the activity of the following: Immunofluorescence techniques. Cells grown on coverslips were fixed for 20 min with 3% paraformaldehyde in phosphate-buffered saline (PBS) and then washed three times in PBS and incubated for 10 min in PBS containing 50 mM NH 4Cl, for 10 min in PBS containing 20 mM glycine, and for 30 min in PBS containing 10% normal goat serum (GS). Subsequently, coverslips were incubated for 1 h at room temperature with primary antibodies at 0.5-1.0 g/ml (anti-porin, Molecular Probes; anti-Mfn2) diluted in PBS containing 10% GS. After a washing in PBS, the coverslips were incubated with fluorochrome-conjugated (Cyanine 5 or Texas Red) goat secondary antibodies for 45 min. Cells were washed three times in PBS prior to mounting in immunofluore medium (ICN Biomedicals). Confocal images were obtained using a Leica TCS 4D laser confocal fluorescence microscope. In other studies, cells were plated in 22-mm glass coverslips and loaded with 100 nM Mitotracker Green for 20 min in culture medium, washed with culture medium, and visualized by live cell imaging in an inverted Leica SP2 confocal microscope. Images were collected using a 488-nm excitation laser and 505-to 530-nm emission spectrum. Acquired images were then processed with ImageJ software (NIH). Cells were classified according their mitochondrial morphology: oval/spheres (only observed in Mfn2 KO cells), short (Ͻ6 m), or long (Ͼ6 m) mitochondria. At least 100 cells per sample were counted in triplicate samples.
Tibialis anterior muscles were removed and fixed in 4% PFA (Santa Cruz) rotating for 1 h and 30 min at 4°C. After being passed through a sucrose gradient from 10 to 30%, muscles were embedded in OCT solution (TissueTek), immediately frozen in liquid nitrogencooled isopenthane (Sigma), and stored at Ϫ80°C; 10-m cryosections of tibialis anterior muscle transfected with pDsRed2-Mito vector were analyzed using a Leica TCS SP2 AOBS Systems confocal scanning microscope. Mitochondrial morphology was analyzed by quantifying the mean of the area of continuous mitochondria found in each slice of the transfected muscle fiber. A custom-made macro for Image J (Fiji) was used (42) .
Mitochondrial DNA extraction and quantification. Mice were euthanized by cervical dislocation, and tissues were immediately frozen for DNA isolation. Total DNA from skeletal muscle was extracted by using the DNAeasy Blood & Tissue Kit (Qiagen) following the manufacturer's recommendations. We quantified mitochondrial DNA by real-time PCR. Total DNA was used as a template and was amplified with specific oligodeoxynucleotides for mitochondrial DNA or SdhA (nuclear gene). Cytochrome c oxidase subunit II in mitochondrial DNA was amplified using the following primers: forward CTACAAGACGCCACAT and reverse GAGAGGGGAGAGCAAT. The primers to amplify nuclear DNA (SdhA) were: Fwd TACTA-CAGCCCCAAGTCT and Rev TGGACCCATCTTCTATGC. We calculated the mitochondrial DNA copy number per cell using SdhA amplification as a reference for nuclear DNA content. PCRs were performed using the ABI Prism 7900 HT real-time PCR machine (Applied Biosystems) and the SYBR Green PCR Master Mix.
Quantitative real-time PCR. OXPHOS subunits mRNA expression was measured by quantitative real-time PCR. Total RNA from skeletal muscle was extracted using a protocol combining TRIzol reagent (Invitrogen) and RNAeasy minikit columns (Qiagen), following the manufacturers' instructions. RNA was reverse-transcribed with the SuperScript RTIII kit (Invitrogen). PCRs were performed using the ABI Prism 7900 HT real-time PCR machine (Applied Biosystems) and the Taqman Probes 20X (Applied Biosystems). All measurements were normalized to ␤-actin expression.
Electrophoresis in native conditions (Blue-native PAGE).
Mitochondrial fractions from skeletal muscles were resuspended in an appropriate volume of buffer A to be at 10 mg/ml (50 mM BisTris, pH 7.0, 1.5 M aminocaproic acid). Mitochondria were solubilized by the addition of digitonin (4 g detergent/g protein) and incubated for 5 min in ice. After a 30-min centrifugation at 13,200 rpm at 4°C, supernatant was collected, and one-third of the final volume of the sample of 5% Serva Blue G dye in 1 M aminocaproic acid was added. The solubilized protein complexes were separated on a 3-13% gradient gel as described elsewhere (41a) and subjected to Western blotting.
Immunoprecipitation assays. Mitochondria (1 mg/ml) were solubilized for 30 min at 4°C in IP buffer (20 mM Tris·HCl, pH 7.4, 150 mM sodium acetate, 2 mM EDTA, 4 mM EGTA, 1 mM PMSF) containing 1% (wt/vol) NP-40. After a clarifying spin, the detergent extracts were incubated with gentle shaking for 2 h at 4°C with the corresponding antibody or preimmune serum bound to protein ASepharose beads. Immunoprecipitates were washed three times for 5 min with 1 ml of solubilization buffer and analyzed by SDS-PAGE.
Western blotting. Total homogenates and mitochondrial fractions were obtained from either cell cultures or tissues, as previously described (37) . The protein obtained was quantified by the BCA method (Pierce).
SDS-PAGE and further densitometric analysis were used to estimate the levels of Mfn2, porin, and subunits of the OXPHOS system in cell extracts or in mitochondrial fractions obtained from skeletal muscle. Thus, samples were run in 10% or 15% acrylamide gels for SDS-PAGE and transferred to Immobilon membranes (Millipore).
The following antibodies were used: Mfn2 (1/1,000, Abcam) and porin (1/5,000, Calbiochem). The antibodies used for the detection of electron transport chain complexes were as follows: anti-NDUFA9 (Complex I), anti-SdhA (Complex II), anti-Uqcrc2, (Complex III), anti-COX IV (Complex IV), and anti-Atp5a1 (Complex V) (1/1,000, Molecular Probes). Proteins were detected by the ECL method (16a) and quantified by scanning densitometry.
Statistical analysis. The data presented here were analyzed using Student's t-test or analysis of variance with an appropriate post hoc test. Data are presented as means Ϯ SE unless stated otherwise. Significance was established at P Ͻ 0.05. have determined the localization of endogenous Mfn2 in tissues. To determine the submitochondrial location of Mfn2, mitochondria were treated with alkaline carbonate or with detergents. Mfn2 behaved as an integral membrane protein based on the resistance to sodium carbonate extraction (Fig. 1A) , and it was solubilized with a number of detergents such as Triton X-100, NP-40, digitonin, or dodecylmaltoside (Fig. 1B) . Mfn2 showed a profile identical to porin, an integral mitochondrial outer membrane protein (Fig. 1, A and B) . To determine whether Mfn2 is in the inner or in the outer membrane in mitochondria, purified mitochondria obtained from heart or brown adipose tissue were subjected to fractionation into outer membranes and mitoplasts. Most of Mfn2 and porin was in the mitochondrial outer membrane, whereas protein COX I was mainly in mitoplasts (Fig. 1C) .
⌬Mfn2 does not modify mitochondrial morphology in cells or in muscle. To study the effect on mitochondrial morphology of the short form of human Mfn2, ⌬Mfn2, lacking residues 614 -757 aa, which encompass the transmembrane domains and the COOH-terminal HR2 region, we transiently transfected different cultured cells. Tranfection of ⌬Mfn2 caused the expression of a 75-kDa Mfn2 form in HeLa cells ( Fig. 2A) . Localization of ⌬Mfn2 analyzed by subcellular fractionation indicated that most of the ⌬Mfn2 protein was localized in the mitochondrial fraction (80% of total) of HeLa cells ( Fig. 2A) . Cytosolic extracts also contained some ⌬Mfn2 protein ( Fig.  2A) . Similar localization of ⌬Mfn2 was detected in hepatoma FaO cells after transfection.
Overexpression of ⌬Mfn2 (together with GFP) in HeLa cells did not alter the morphology of mitochondrial filaments compared with nontransfected cells (not labeled with GFP), indicating that this form of Mfn2 shows no mitochondrial fusion activity (Fig. 2B ). This observation is in keeping with previous data indicating that a similar truncated Mfn2 protein, hMfn2⌬602-757, shows no mitochondrial fusion activity in cultured cells (37) . Expression of ⌬Mfn2 in hepatoma FaO cells also showed no alteration of mitochondrial morphology. To study whether ⌬Mfn2 normalized mitochondrial morphology in Mfn2 knockout MEF cells, ⌬Mfn2, was expressed via adenoviral transduction. ⌬Mfn2 did not cause any alteration in the morphology of mitochondria (Fig. 2C) . These data indicate that ⌬Mfn2 does not show mitochondrial fusion activity.
Mouse skeletal muscles were electroporated with cDNA encoding ⌬Mfn2 and DsRed2-Mito vector, and mitochondrial morphology was analyzed in muscles after 8 days of electroporation. A third group, consisting of skeletal muscle-specific KO mice, was also studied. The mitochondrial network was visualized by confocal microscopy of tibialis anterior muscle, and no changes were detectable upon ⌬Mfn2 expression (Fig.  2D ). Under these conditions, a reduced mitochondrial network was detected in Mfn2-ablated muscles (Fig. 2D) .
⌬Mfn2 activates mitochondrial metabolism in cells. To determine whether ⌬Mfn2 alters mitochondrial metabolism, C 2 C 12 myotubes (after 3 days of differentiation) were transduced with adenoviruses encoding ⌬Mfn2 or with control adenoviruses (Adv-GFP). This approach also caused the expression of a 75-kDa Mfn2 form (Fig. 3A) . Under these conditions, the expression of the endogenous form of Mfn2 or the expression of porin (a marker of mitochondrial mass) remained unaltered (Fig. 3B) . The expression of the ⌬Mfn2 was 7.4 Ϯ 1.5-fold greater than the endogenous expression of Mfn2.
Myotubes overexpressing ⌬Mfn2 showed an increased oxygen consumption rate measured under routine conditions (5.5 mM glucose) compared with control cells (Fig. 3C) . In addition, the maximal rate of oxygen consumption (E; measured in the presence of the uncoupler FCCP) was also increased in the ⌬Mfn2 group (Fig. 3D) . No differences in oxygen consumption in the presence of the inhibitor oligomycin were detected (Fig. 3E) . The routine flux control ratio (R/E) was similar in control and ⌬Mfn2 groups and was indicative that myotubes use only 23% of their respiratory capacity under routine conditions. In addition, the phosphorylation respiratory control ratio [(R-L)/E] and leak flux control ratio (L/E) were similar in control and ⌬Mfn2 groups and revealed a strong coupling of the OXPHOS system (almost 21% of the maximal respiratory capacity is used for ATP production and less than 3% represents the uncoupled respiration; Fig. 3F ).
An opposite pattern of changes was detected in C 2 C 12 myotubes upon silencing of Mfn2 induced by transduction with a Mfn2 miRNA (Fig. 4A) . Mfn2-silenced cells showed enhanced routine respiration (Fig. 4B) , unaltered maximal mitochondrial respiration (Fig. 4C) , and enhanced oligomycininsensitive respiration (Fig. 4D) . The R/E and the (R-L)/E were similar in control and Mfn2-silenced groups, whereas the L/E was greater in Mfn2-deficient cells (Fig. 4E) . Overexpression of ⌬Mfn2 in hepatoma FaO cells (Fig. 5A ) by adenoviral infection also increased oxygen consumption under routine conditions due to an increase in the maximal respiratory capacity of the cells (E value; Fig. 5, B and C) . These data indicate that the ⌬Mfn2 form activates mitochondrial respiration and that this action is independent of the cellular context. ⌬Mfn2 activates mitochondrial metabolism in skeletal muscle. We next analyzed the effect of ⌬Mfn2 on mouse skeletal muscle metabolism. To this end, mouse skeletal muscles were electroporated with cDNA encoding ⌬Mfn2, and muscles were studied after 2 wk of electroporation. Electroporation caused the expression of the ⌬Mfn2 band, which was somewhat more abundant than the endogenous Mfn2 protein (1.5 Ϯ 0.3-fold greater; Fig. 6A ). The expression of ⌬Mfn2 did not alter the expression of endogenous Mfn2 (Fig. 6B) . ⌬Mfn2 caused enhanced glucose oxidation and a higher (R-L)/E in muscles (Fig. 6, C and D) , which occurred in the absence of significant changes in absolute levels of oxygen consumption under basal conditions or in the presence of ADP or FCCP (Fig. 6E) . Under these conditions, expression of protein subunits encoding for Cox IV and Atp5a1, and the activities of respiratory Complexes IϩIII and III were increased in muscles expressing ⌬Mfn2 (Fig. 7, A and B) . The expression of genes encoding the OXPHOS subunits was not altered (Fig. 7C) . No changes were detected in mitochondrial DNA copy number ( Fig. 7D ) or in porin expression (Fig. 6B) . The changes in muscle respiration took place in conditions in which the weight of electroporated muscles was unaltered. In addition, ⌬Mfn2 expression did not alter circulating concentrations of glucose or insulin.
On the basis of the observation that ⌬Mfn2 stimulates respiratory chain activity, we analyzed whether this effect correlates with the stability of the respiratory complexes or respiratory supercomplexes. To this end, mitochondrial fractions from mouse tibialis anterior muscles were subjected to electrophoresis under native conditions (Blue Native) after electroporation with control or ⌬Mfn2 vectors. Muscles were solubilized with digitonin under conditions in which supercomplexes are maintained (4 g digitonin/g of protein) (1). This procedure allowed the detection of five bands corresponding to the respiratory complexes (an ϳ980-kDa band corresponding to the monomeric form of Complex I; an ϳ600-kDa band corresponding to the monomeric form of Complex V; a 500-kDa band corresponding to the dimeric form of Complex III; an ϳ200-kDa band of the monomeric Complex IV, and a 130-kDa band corresponding to the monomeric form of Complex II), and two high-molecular-weight bands corresponding to the supercomplexes IϩIII and IϩIIIϩIV (Fig. 8A ). These observations are in keeping with prior studies reporting the presence of supercomplexes in skeletal muscle (34, 38) . Overexpression of ⌬Mfn2 did not modify the abundance of the monomeric Complexes I, II, IV, and V or the dimeric Complex III in skeletal muscle (Fig. 8B) . However, the abundance of superComplexes IϩIII and IϩIIIϩIV was modified. The proportion of form IϩIIIϩIV over the monomeric I form was significantly enhanced in muscles overexpressing ⌬Mfn2 (Fig.  8C) . The increased abundance of supercomplexes is consistent with the greater activities of Complexes IϩIII and III. In all, these observations indicate that ⌬Mfn2 enhances mitochondrial metabolism and glucose oxidation in skeletal muscle. These effects may be exerted through local processes and are independent of alterations in mitochondrial mass.
⌬Mfn2 activates metabolism in liver cells. ⌬Mfn2 expression caused a marked enhancement of the basal net glucose production from lactate/pyruvate in hepatoma FaO cells (Fig. 9A) . Dexamethasone also enhanced gluconeogenesis from lactate and pyruvate, and under those conditions no effects of ⌬Mfn2 were detected (Fig. 9A) . In contrast, glucose production from a dihydroxyacetone remained unaltered upon ⌬Mfn2 expression (Fig. 9B) . Taken together, these data demonstrate that ⌬Mfn2 regulates output of glucose by gluconeogenesis in FaO cells from substrates that undergo mitochondrial steps.
To determine whether ⌬Mfn2 also regulates gluconeogenesis in vivo, we used adenoviral vectors. Viruses containing the cDNA encoding ⌬Mfn2 or green fluorescent protein (CMV-GFP adenovirus) were injected into C57BL6J mice. Assays of blood aspartate aminotransferase activity ensured that there was no hepatotoxicity in these experiments. Injection of ⌬Mfn2 adenoviruses induced the expression of this protein in liver but not in heart, skeletal muscle, or adipose tissue (Fig. 10A) . Five days after virus administration, mice were fasted for 16 h and subjected to a pyruvate challenge. In fasting mice, pyruvate is shuttled through the gluconeogenic pathway in the liver and ultimately converted to glucose. Thus, by measuring blood glucose after an intraperitoneal injection of a pyruvate bolus, we obtain a physiological readout of the relative activity of the enzymes of the gluconeogenic pathway. Mice expressing ⌬Mfn2 showed higher glycemia and plasma insulin levels after fasting (Fig.  10, B and C) . In addition, following an injection of pyruvate, mice expressing ⌬Mfn2 produced significantly more glucose than the control group (Fig. 10D) . Under these conditions, mice expressing ⌬Mfn2 did not show significant changes in PEPCK or G6Pase mRNAs (Fig. 10E) . In all, the increased fasting glycemia and increased glucose production from pyruvate indicate that ⌬Mfn2 accelerates gluconeogenesis in the liver.
The stimulatory effect of ⌬Mfn2 on mitochondrial respiration requires endogenous Mfn2. To get some information on the mechanisms required for the effects of ⌬Mfn2 on mitochondrial metabolism, we analyzed the impact of ⌬Mfn2 on 
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Control ∆Mfn2 Fig. 6 . Effects of expression of ⌬Mfn2 on skeletal muscle metabolism. Muscles from 10-to 12-wk-old mice were electrotransferred with control or ⌬Mfn2 vector, and muscles were collected 14 days after electrotransfer. A: Mfn2 protein expression in total lysates of muscles. B: quantification of endogenous Mfn2 and porin protein expression in total lysates of muscles. C: glucose oxidation assays were performed in tibialis muscles (n ϭ 15/group). D: respiratory control ratio was measured as the ratio of O2 flux with (state 3) and without (state 4) ADP. E: oxygen consumption in state 3 and state 4 was measured in permeabilized fibers from tibialis muscle, with Complex I substrates (glutamate ϩ malate). Maximal respiratory capacity, or state 3u, was assessed after addition of the uncoupler FCCP (n ϭ 6 mice per group). Data represent means Ϯ SE. *P Ͻ 0.05.
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A FORM OF MFN 2 WITHOUT FUSION ACTIVITY ENHANCES METABOLISM mitochondrial respiration in control and in Mfn2-silenced C 2 C 12 myoblasts (Fig. 11A) . Expression of human ⌬Mfn2 caused a stimulation of basal and maximal oxygen consumption in control C 2 C 12 mouse muscle cells (Fig. 11B) . In contrast, Mfn2-deficient cells did not show any stimulation of mitochondrial respiration upon expression of ⌬Mfn2 (Fig.  11C) . In all, these results suggest that ⌬Mfn2 requires the activity of endogenous Mfn2. 
Mfn2 interacts with mitochondrial respiratory Complexes I and II.
To get further insight into the mechanisms by which Mfn2 stimulates mitochondrial metabolism, we analyzed whether Mfn2 physically interacts with some of the respiratory complexes. Thus, we assayed whether Mfn2 coimmunoprecipitates with subunits of different respiratory complexes. Purified mitochondria obtained from rat heart were subjected to immunoprecipitation using antibodies directed against Mfn2 (Fig. 12) . Assays resulted in substantial immunoprecipitation of Mfn2 (Fig. 12A) . Aliquots of the immune pellets were subjected to Western blot with antibodies that specifically recognize proteins present in respiratory Complexes I, II, III, IV, and V. Subunit p39 from Complex I and protein p70 from Complex II specifically coimmunoprecipitated with Mfn2 in immune pellets (Fig.  12A ). This association was not found with subunits of Complexes III, IV, or V (Fig. 12A) . Other mitochondrial proteins such as porin or cytochrome c were not coimmunoprecipitated either (Fig. 12A) .
Mfn2 immunoprecipitation assays were also performed from mitochondria obtained from HeLa cells overepressing human Mfn2 (Fig. 12B) . Human Mfn2 was also specifically immunoprecipitated (Fig. 12B) , and under these conditions protein p70 from Complex II was again specifically detected in immune pellets (Fig. 12B) . Protein p39 from Complex I was expressed at low levels in HeLa cells and did not coimmunoprecipitate with Mfn2 (Fig. 12B ).
DISCUSSION
Here, we demonstrate that a short form of Mfn2 (⌬Mfn2) lacking mitochondrial fusion activity shows remarkable biological activities in muscle and liver cells. Thus, cells expressing ⌬Mfn2 showed enhanced mitochondrial respiration. ⌬Mfn2 also increased the abundance of some OXPHOS subunits and enhanced activities of respiratory Complexes IϩIII and III in muscle, and as a result, ⌬Mfn2 enhanced glucose oxidation. In addition, ⌬Mfn2 stimulated gluconeogenesis from pyruvate in liver. The metabolic effects of ⌬Mfn2 do not depend on mitochondrial fusion activity, since mitochondrial morphology remained unchanged, and they may require the presence of endogenous Mfn2. We propose a model by which ⌬Mfn2 interacts with a complex constituted by endogenous Mfn2 and respiratory Complexes I and II.
The biological effects of ⌬Mfn2 are helpful to understanding the biology of Mfn2 in cells and tissues. Overexpression of ⌬Mfn2 in muscle or in hepatoma cells caused enhanced basal and maximal respiration rates (Figs. 3 and 5) . Expression of ⌬Mfn2 in skeletal muscle enhanced glucose oxidation and the respiratory control ratio (Fig. 6 ). This pattern of changes is opposite to the alterations detected upon Mfn2 loss of function. Thus, Mfn2 deficiency in muscle or in hepatoma cells causes an enhanced respiratory leak (Fig. 4) (25) . Furthermore, Mfn2 ablation of skeletal muscle reduced glucose oxidation and the respiratory control ratio (44) . In all, our data are coherent with a role of Mfn2 promoting mitochondrial metabolism in tissues. Indeed, these data are fully consistent with prior observations indicating that Mfn2 loss of function reduces mitochondrial activity in muscle cells (4, 11, 37) as well as in skeletal muscle and liver (44) . In this regard, increasing evidence indicates that conditions characterized by insulin resistance or deficient mitochondrial metabolism, such as human obesity or type 2 diabetes, are associated with repressed Mfn2 (3). These conditions include the classical form of type 2 diabetes linked to obesity, nonobese type 2 diabetes, and early-onset type 2 diabetes (3, 26) . Furthermore, bariatric surgery-induced weight loss in morbidly obese subjects induces Mfn2 expression in skeletal muscle (3, 24, 36) . In all, these data allow us to propose that Mfn2 plays a regulatory role in metabolism, and it may be key in the pathophysiology of obesity or type 2 diabetes.
Our data in hepatoma FaO cells and in mouse liver indicate that ⌬Mfn2 stimulates gluconeogenic activity. These data are coherent with the reduced gluconeogenesis from lactate/pyruvate reported in FaO cells upon Mfn2 silencing (25) . The effects of ⌬Mfn2 are not a consequence of changes in the expression of gluconeogenic genes and may be a consequence of enhanced mitochondrial pyruvate uptake or enhanced TCA activity. In fact, this view is in keeping with evidence indicating that pyruvate carboxylase and its mitochondrial uptake controls the gluconeogenic flux in hepatocytes (19, 20) , and the observations that TCA activity is linked to hepatic gluconeo- genesis (7, 50) . Of note, the alterations in liver metabolism associated with the hepatic expression of ⌬Mfn2 caused enhanced circulating glucose and insulin under fasting. In fact, elevated glucose and a compensatory increase of insulin are hallmarks of increased hepatic glucose output in fasted nondiabetic animals, suggesting that they are secondary to enhanced gluconeogenesis. Expression of ⌬Mfn2 caused a pattern of changes in cell respiration that was similar in hepatoma FaO cells and in myotubes, indicating that the effects of the Mfn2 protein are detectable in different cell contexts. ⌬Mfn2 enhanced oxygen consumption under routine and under maximally stimulated conditions in both cell types, and this occurred in the absence of alterations in the rate of proton leak. These data suggest that the higher rates of oxygen consumption are not explained by reduced mitochondrial energy efficiency caused by proton leak (46, 48) . Furthermore, the effects of ⌬Mfn2 were independent of changes in mitochondrial mass, as assessed by porin expression. These results are in keeping with data obtained in cells or in tissues upon Mfn2 loss of function. Under those conditions, Mfn2 deficiency caused mitochondrial dysfunction, which was characterized by enhanced respiratory leak, and unchanged mitochondrial mass (25, 44) .
On the basis of all these data, we propose that ⌬Mfn2 accelerates respiration by activating the maximal rate of electron transport chain. Indeed, studies in mouse skeletal muscle also support this view. Expression of ⌬Mfn2 in skeletal muscle enhanced glucose oxidation and the respiratory control ratio. These muscles also showed an increased activity of Complexes IϩIII and Complex III and an increased abundance of some OXPHOS subunits and respiratory supercomplexes. We suggest that ⌬Mfn2 favors the formation/stability of respiratory supercomplexes and that this is instrumental in the enhanced efficiency of the respiratory chain (23, 41) . In keeping with this view, expression of ⌬Mfn2 in skeletal muscle enhanced the expression of COX IV or Atp5a1 subunit proteins, which occurred in the absence of alterations in mRNA levels.
The short form of Mfn2 used in this study lacks the two membrane-spanning domains and does not alter mitochondrial morphology in cells or in muscles. Consequently, the metabolic activity of ⌬Mfn2 does not seem to be directly dependent on mitochondrial fusion and may be more related to structural information emanating from Mfn2. In this respect, we have learned some relevant aspects of Mfn2 biology in this study. Mfn2 in muscles and brown adipose tissues behaves as an outer mitochondrial membrane protein. Despite this, Mfn2 interacts with respiratory complexes I and II, which are localized at the inner mitochondrial membrane. Thus, the p39 subunit of Complex I and the p70 subunit of Complex II coimmunoprecipitate with Mfn2 from cardiac mitochondria extracts. In addition, the (9, 16, 21) . Based on this, Mfn2 may stimulate mitochondrial respiration via participation in a complex together with respiratory complexes. Along these lines, we have documented that the stimulatory effects of ⌬Mfn2 on mitochondrial respiration require the activity of endogenous Mfn2. This suggests that ⌬Mfn2 interacts with endogenous Mfn2 or with a complex dependent on Mfn2. A nonexclusive possibility is that ⌬Mfn2 activity impacts on the cardiolipin composition of the inner mitochondrial membrane. Cardiolipins are key components for the association of the respiratory supercomplexes (10, 28, 52, 53) . This is coherent with the increased proportion of respiratory supercomplexes, the activity of the respiratory complexes, and the maximal OXPHOS capacity detected upon ⌬Mfn2 expression. In this connection, cardiolipin remodeling induced by upregulation of lysocardiolipin acyltransferase-1 negatively controls Mfn2 expression, leading to mitochondrial fragmentation (31) . Further studies are required to prove these hypotheses.
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